264 related articles for article (PubMed ID: 31163334)
1. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence.
Seufferlein T; Hammel P; Delpero JR; Macarulla T; Pfeiffer P; Prager GW; Reni M; Falconi M; Philip PA; Van Cutsem E
Cancer Treat Rev; 2019 Jul; 77():1-10. PubMed ID: 31163334
[TBL] [Abstract][Full Text] [Related]
2. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
Oncologist; 2016 Feb; 21(2):178-87. PubMed ID: 26834159
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer.
Chen Z; Lv Y; Li H; Diao R; Zhou J; Yu T
Medicine (Baltimore); 2021 Jan; 100(3):e24068. PubMed ID: 33546009
[TBL] [Abstract][Full Text] [Related]
5. Complete pathological remission of locally advanced, unresectable pancreatic cancer (LAPC) after intensified neoadjuvant chemotherapy.
Hartlapp I; Müller J; Kenn W; Steger U; Isbert C; Scheurlen M; Germer CT; Einsele H; Kunzmann V
Onkologie; 2013; 36(3):123-5. PubMed ID: 23486001
[TBL] [Abstract][Full Text] [Related]
6. Nontrial, real-world outcomes in unresectable locally advanced pancreatic cancer: Chemotherapy and chemoradiation is the standard while surgery is uncommon.
Ramaswamy A; Jandyal S; Ostwal V; Engineer R; Lewis S; Bose S; Pande N; Shrikhande SV
Indian J Cancer; 2017; 54(3):530-534. PubMed ID: 29798952
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
8. Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study.
van Veldhuisen E; Walma MS; van Rijssen LB; Busch OR; Bruijnen RCG; van Delden OM; Mohammad NH; de Hingh IH; Yo LS; van Laarhoven HW; van Leeuwen MS; Nio CY; van Santvoort HC; de Vries J; Wessels FJ; Wilmink JW; Molenaar IQ; Besselink MG; van Lienden KP;
HPB (Oxford); 2019 Oct; 21(10):1385-1392. PubMed ID: 31010633
[TBL] [Abstract][Full Text] [Related]
9. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma.
Khushman M; Dempsey N; Maldonado JC; Loaiza-Bonilla A; Velez M; Carcas L; Dammrich D; Hurtado-Cordovi J; Parajuli R; Pollack T; Harwood AP; Macintyre J; Tzeng CW; Merchan JR; Restrepo MH; Akunyili II; Ribeiro A; Narayanan G; Portelance L; Sleeman D; Levi JU; Lima CM; Hosein PJ
Pancreatology; 2015; 15(6):667-73. PubMed ID: 26412296
[TBL] [Abstract][Full Text] [Related]
10. Localized Pancreatic Cancer: Multidisciplinary Management.
Coveler AL; Herman JM; Simeone DM; Chiorean EG
Am Soc Clin Oncol Educ Book; 2016; 35():e217-26. PubMed ID: 27249726
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta-Analysis.
Damm M; Efremov L; Birnbach B; Terrero G; Kleeff J; Mikolajczyk R; Rosendahl J; Michl P; Krug S
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503138
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for pancreatic cancer.
Springfeld C; Jäger D; Büchler MW; Strobel O; Hackert T; Palmer DH; Neoptolemos JP
Presse Med; 2019 Mar; 48(3 Pt 2):e159-e174. PubMed ID: 30879894
[TBL] [Abstract][Full Text] [Related]
13. Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled trial.
Walma MS; Rombouts SJ; Brada LJH; Borel Rinkes IH; Bosscha K; Bruijnen RC; Busch OR; Creemers GJ; Daams F; van Dam RM; van Delden OM; Festen S; Ghorbani P; de Groot DJ; de Groot JWB; Haj Mohammad N; van Hillegersberg R; de Hingh IH; D'Hondt M; Kerver ED; van Leeuwen MS; Liem MS; van Lienden KP; Los M; de Meijer VE; Meijerink MR; Mekenkamp LJ; Nio CY; Oulad Abdennabi I; Pando E; Patijn GA; Polée MB; Pruijt JF; Roeyen G; Ropela JA; Stommel MWJ; de Vos-Geelen J; de Vries JJ; van der Waal EM; Wessels FJ; Wilmink JW; van Santvoort HC; Besselink MG; Molenaar IQ;
Trials; 2021 Apr; 22(1):313. PubMed ID: 33926539
[TBL] [Abstract][Full Text] [Related]
14. Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer.
Rombouts SJ; Walma MS; Vogel JA; van Rijssen LB; Wilmink JW; Mohammad NH; van Santvoort HC; Molenaar IQ; Besselink MG
Ann Surg Oncol; 2016 Dec; 23(13):4352-4360. PubMed ID: 27370653
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.
Lakatos G; Petranyi A; Szűcs A; Nehéz L; Harsanyi L; Hegyi P; Bodoky G
Pathol Oncol Res; 2017 Oct; 23(4):753-759. PubMed ID: 28062950
[TBL] [Abstract][Full Text] [Related]
16. Induction Therapy in Localized Pancreatic Cancer.
Shaib WL; Sayegh L; Zhang C; Belalcazar A; Ip A; Alese OB; Akce M; Wu C; Qu Y; Maithel SK; Kooby D; Cardona K; Sarmeinto JM; El-Rayes BF
Pancreas; 2019 Aug; 48(7):913-919. PubMed ID: 31268982
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
[TBL] [Abstract][Full Text] [Related]
18. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer.
Lutz MP; Zalcberg JR; Ducreux M; Aust D; Bruno MJ; Büchler MW; Delpero JR; Gloor B; Glynne-Jones R; Hartwig W; Huguet F; Laurent-Puig P; Lordick F; Maisonneuve P; Mayerle J; Martignoni M; Neoptolemos J; Rhim AD; Schmied BM; Seufferlein T; Werner J; van Laethem JL; Otto F
Eur J Cancer; 2017 Jul; 79():41-49. PubMed ID: 28460245
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-based split stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: study protocol of a prospective, single-arm phase II trial.
Zheng R; Wang C; Huang X; Lin Q; Huang D; Li XB; Huang H; Xu B
BMJ Open; 2020 Nov; 10(11):e039900. PubMed ID: 33154057
[TBL] [Abstract][Full Text] [Related]
20. Upfront surgery vs. neoadjuvant therapy for resectable pancreatic cancer: a narrative review of available evidence.
Ratnayake CBB; Roberts KJ; Pandanaboyana S
Chin Clin Oncol; 2022 Feb; 11(1):2. PubMed ID: 35184565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
